Latest KFF Health News Stories
5 formas en las que el sistema colapsaría si se eliminara la ley de salud
No solo las disposiciones más prominentes del Obamacare se verían afectadas si se considera a la ley inconstitucional.
5 Ways Nixing The Affordable Care Act Could Upend The Entire Health System
There could be a long legal struggle ahead over the decision by a judge in Texas to invalidate the federal health law. But if his decision stands, it would have long-lasting effects on health care from insurance coverage to Medicare payments to privacy protections.
Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.
Para los abuelos: nuevo Apple Watch monitorea caídas y el ritmo cardíaco
El nuevo dispositivo de Apple apunta a un grupo demógrafico distinto al de los fanáticos de la tecnología: los adultos mayores.
In Grandma’s Stocking: An Apple Watch To Monitor Falls, Track Heart Rhythms
The new-generation gadget is designed to alert and protect wearers from falls and heart problems, expanding Apple’s target audience beyond the usual, tech-savvy, early adopters to those with older tickers.
Government Investigation Finds Flaws In the FDA’s Orphan Drug Program
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Podcast: KHN’s ‘What The Health?’ Reading The Tea Leaves In Blue Wave’s Wake
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN’s Jay Hancock about the latest “Bill of the Month.”
Podcast: KHN’s ‘What The Health?’ Health Nerd Books For The Holidays
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Joanne Kenen of Politico and Anna Edney of Bloomberg News discuss the latest on open enrollment for the Affordable Care Act and Medicare; new moves by the Food and Drug Administration to regulate tobacco and nicotine products; and whether House Democrats will pursue a “Medicare-for-all” bill in the next Congress. Plus, for extra credit, the panelists recommend their favorite health policy books for your holiday reading and gifting pleasure.
Fish Oil Drug Looks Heart-Healthy. Just Don’t Swallow It Hook, Line And Sinker.
The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didn’t find the same promise for over-the-counter fish oil supplements when tested in healthy people.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Heart Drug Spotlights Troubling Trends In Drug Marketing
Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.
Estudio revela sustancias prohibidas y peligro en suplementos de venta libre
Un estudio halló que suplementos de venta libre para dietas, músculos e incluso para mejor desempeño sexual contenían contaminantes y sustancias prohibidas.
Hidden Drugs And Danger Lurk In Over-The-Counter Supplements, Study Finds
Dieters and gym rats, beware. Some dietary supplements promising weight loss or more muscle may contain active ingredients not listed on the label that fly under the radar of the Food and Drug Administration. The California Department of Public Health analyzed public data maintained by the FDA to suss out trends among tainted products, raising red flags.
Podcast: KHN’s ‘What The Health?’ Falling Premiums And Rising Political Tensions
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administration’s announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.
The Feds’ Termination Of A Tiny Contract Inflames Bitter Fight Over Fetal Tissue
Just weeks before midterm elections, a move by federal health officials spotlights a contentious issue: the use of human fetal tissue in research. Here’s what you need to know to understand the debate.
Podcast: KHN’s ‘What The Health?’ Some Things Old, Some Things New
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner discuss final action on bills in Congress to address the opioid epidemic and fund federal health agencies. They also look at new efforts by the Food and Drug Administration to crack down on teen nicotine use.
Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.
Buried In Congress’ Opioid Bill Is Protection For Personal Drug Imports
The protection is a win for people who get their needed, legitimate drugs from overseas.
As States Try To Rein In Drug Spending, Feds Slap Down One Bold Medicaid Move
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren’t proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.
